Related by context. All words. (Click for frequent words.) 71 LY# [002] 65 MAGE A3 ASCI 65 orally administered inhibitor 65 AAG geldanamycin analog 64 trastuzumab Herceptin R 64 elotuzumab 64 XL# anticancer compounds 64 MORAb 64 receiving INTRON 64 investigational compound 64 Cytogen marketed 63 Telik logo TELINTRA 63 LEP ETU 63 LymphoStat B belimumab 63 investigational compounds 63 Mg Uk 63 oral prodrug 63 lexidronam injection 63 INSPIRE Trial Phase III 63 MKC# MT 63 Contrave# 63 investigational humanized monoclonal antibody 63 markets Testim ® 63 interferon gamma 1b 63 virus HCV protease inhibitor 62 samarium Sm 62 SPRYCEL ® 62 MKC# 62 forodesine 62 lintuzumab SGN 62 Epothilone D 62 Completes Patient Enrollment 62 huC# DM4 62 arsenic trioxide injection 62 PRN FDA Approves 62 GABITRIL 62 TELINTRA 62 pan HDAC inhibitor 62 compound ITMN 62 CRx 62 peptidic compound 62 Tezampanel 62 novel synthetic PEGylated 61 SILENOR 61 Presents Preclinical 61 metaglidasen 61 DISCLOSURE NOTICE 61 Xcytrin R 61 markets HP Acthar 61 PEG PAL 61 please visit www.sucampo.com 61 TM Aganocide 61 generation Hsp# inhibitor 61 Mg Usa 61 K ras mutations 61 compound INCB# 61 ALN PCS 61 please visit www.abraxane.com 61 hoFH 61 pulmonology portfolio 61 Naproxen sodium 61 http:/www.pharmion.com 61 dextromethorphan quinidine 61 lesinurad 61 pralatrexate injection folate analogue 61 monoclonal antibody IgG1 Mab 61 MPS IVA 61 developing ostarine selective 61 Panzem R 61 PEG SN# 60 investigational monoclonal antibody 60 website www.octoplus.nl 60 AzaSite Plus 60 IAP inhibitors 60 ALN HPN 60 hypoxia activated prodrug 60 pan histone deacetylase 60 DOS# 60 induced mucositis 60 Syncria 60 PNP inhibitor 60 HCV protease inhibitors 60 AEG# 60 non nucleoside inhibitor 60 mertansine 60 nalbuphine ER 60 IMiDs ® 60 novel topoisomerase 60 agonistic human 60 adenosine injection 60 FOLOTYN ® 60 docetaxel Taxotere R 60 Pruvel ™ 60 Initiates Phase II 60 refractory gout 60 panitumumab Vectibix 60 MAA submission 60 LY# [003] 60 PEGylated Fab fragment 60 IMiDs 60 evaluating bafetinib 60 Submits Response 60 CYT# potent vascular disrupting 60 Meets Primary Endpoint 60 2 methoxyestradiol 60 corticotropin injection 60 evaluating satraplatin 60 phase IIb trial 60 diarrhea predominant irritable 60 oral picoplatin 60 INCB# [001] 60 Zorbtive TM 60 novel VDA molecule 60 sodium glucose cotransporter 60 QUADRAMET R 60 CORLUX CORT # 60 histone deacetylase HDAC inhibitor 60 developing ACAPODENE 60 Begins Dosing 60 myelodysplastic myeloproliferative diseases 60 enzastaurin 60 please visit http:/www.atherogenics.com 60 Empatic ™ 60 visit www.oncolyticsbiotech.com 60 generation proteasome inhibitor 60 approved incretin mimetic 59 Initiates Phase 59 inhibit KSP 59 SAR# [002] 59 http:/www.memorypharma.com 59 Personalized Immunotherapy 59 OR SIMILAR STATEMENTS ARE 59 PS# [001] 59 reflect GuestLogix 59 oral nucleoside analogue 59 reduce serum phosphate 59 XP# XP# 59 pentadentate logo R 59 Pimavanserin 59 TRIOLEX HE# APOPTONE HE# 59 IMPDH inhibitor 59 anaphylactic reactions bronchospasm 59 Xeloda ® 59 humanized interleukin 6 59 Initiates Clinical Trial 59 Peginterferon alfa 2b 59 MultiCell bases 59 OMNARIS HFA 59 Solazed TM 59 HGS ETR2 59 allosteric modulator PAM 59 IL# PE#QQR 59 Zemiva TM 59 BEMA Buprenorphine 59 humanized therapeutic 59 mGluR5 NAM 59 alvespimycin 59 Solorel TM 59 orally bioavailable mimics 59 gastrin analogue TT 59 anti amnesic 59 NU# direct 59 oral ridaforolimus 59 Ixempra 59 HCV NS5B polymerase 59 mitotic kinesins 59 LPM TM 59 Azedra TM Onalta TM 59 vapreotide acetate 59 Phase 2b Clinical Trial 59 VEGFR2 inhibitor 59 inflammatory autoimmune diseases 59 IgG1 monoclonal antibody 59 Zemiva ™ 59 Tekturna HCT 59 selective modulator 59 Kuvan R 59 Refractory Hodgkin Lymphoma 59 cannabinor 59 interferon alfacon 1 59 Ozarelix 59 Achieves Primary Endpoint 59 budesonide foam 59 MCSP respectively 59 oncolytic virus therapies 59 mg q#h 59 Bezielle 59 ZOLINZA 59 Ostarine ™ 59 Phase Ib clinical trials 59 MyVax R 59 neuropathic pain metabolic diseases 59 ARCOXIA 59 CCX# 59 Serious adverse reactions 59 balsalazide 59 PSMA ADC 59 FENTORA 59 regarding allosteric modulators 59 Commences Phase 59 Auxilium anticipates 59 non nucleoside HCV 59 Zenvia ™ 59 includes TOLAMBA TM 59 Archexin 59 JAK inhibitor 58 HCV polymerase inhibitors 58 R roscovitine CDK cyclin 58 products MKC# PP 58 Trial Evaluating 58 ARIKACE ™ 58 CORT # 58 R lenalidomide 58 TBC# 58 statin monotherapy 58 please visit http:/www.supergen.com 58 mg eq 58 rusalatide acetate 58 receptor inhibiting monoclonal 58 RhuDex R 58 reflect Ronn Motors 58 Vicriviroc 58 Neulasta R 58 Triolex 58 XL# XL# XL# XL# 58 CCR9 antagonist 58 R#/MEM # 58 cetuximab Erbitux R 58 Investigational Compound 58 novel histone deacetylase 58 TRIOLEX ™ 58 dasatinib Sprycel ® 58 Pivotal Phase 58 TRACON Pharmaceuticals 58 nonclinical studies 58 EXPECTED RESULTS MAY INCLUDE 58 CD# CEA 58 ATRA IV 58 adecatumumab MT# 58 AEGR 58 candidate XP# 58 Dyax logo 58 R sorafenib tablets 58 Exelixis compounds 58 nucleotide analog 58 octreotide implant 58 Benazepril 58 RhuDex TM 58 BY MAKING THESE 58 Phenoptin 58 Genentech Rituxan 58 urocortin 2 58 PDE4 inhibitor 58 PEGylated irinotecan 58 www.medicago.com 58 evaluating tivozanib 58 Oncolytics please 58 SearchHelp communications 58 BiovaxID TM 58 Reports Preclinical Data 58 FOLFOX6 chemotherapy regimen 58 BUPHENYL 58 polymerase inhibitor 58 www.vivus.com 58 Ophena TM 58 visit www.targanta.com 58 KSP inhibitor 58 mapatumumab 58 refractory chronic lymphocytic 58 davunetide intranasal AL 58 tanespimycin 58 alemtuzumab Campath 58 forward lookinginformation 58 Sulonex TM 58 oral gallium 58 MEK Inhibitor 58 Presents Preclinical Data 58 humanised monoclonal antibody 58 IMiDs R 58 Selzentry Celsentri 58 Investigational Oral 58 developing Bicifadine serotonin 58 posaconazole 58 sorafenib tablets 58 FUSILEV ® 58 5 FU leucovorin 58 polysaccharide polymer 58 CDK cyclin dependent 58 JVRS 58 μg dose 58 zanolimumab 58 XL# XL# 58 forward.looking statements 58 formerly LymphoStat B 58 adalimumab Humira 58 CysDisplay R 58 visit www.unigene.com 58 Atripla combines 58 Thesestatements 58 peripherally acting 58 Balchem expectation 58 PLACE UNDUE IMPORTANCE ON 58 AN# topical anti 58 R roscovitine 58 CIP TRAMADOL ER 58 paclitaxel Taxol ® 58 AND OBJECTIVES OR 57 NS#/#A protease 57 please visit www.medicinova.com 57 R rilonacept Injection 57 PDX pralatrexate 57 LymphoStat B TM 57 intranasal formulation 57 selective androgen receptor modulators 57 PURPOSE OF SAFE HARBOR 57 selective kinase inhibitor 57 Azedra 57 TRAIL receptor antibodies 57 candidate AQ4N 57 please visit www.eisai.com 57 Infusion Reactions Severe 57 TKB# 57 chemically modified tetracyclines 57 C1 INH deficiency 57 Combination REOLYSIN R 57 constituteforward looking 57 rasagiline tablets 57 Geac intentions 57 drug pipeline TAFA# 57 ularitide 57 PROSTASCINT R 57 within themeaning 57 PEGylated anti 57 CTAP# Capsules 57 Initiates Enrollment 57 treat chronic sinusitis 57 Dapagliflozin 57 dependent kinase inhibitor 57 leukemia AML 57 liposomal formulation 57 secretory phospholipase A2 57 SIRT1 activators 57 P#X# antagonist 57 dopamine partial agonist 57 ARE USED THEY IDENTIFY 57 Crofelemer budesonide foam 57 cMET 57 YONDELIS 57 Thalomid ® 57 Vaccine Adjuvant 57 OTCQB CTIX 57 prokinetic agent 57 SinuNase ™ 57 HGS ETR1 57 Randomized Phase 57 multi kinase inhibitor 57 LOOKING INFORMATION 57 hyaluronidase enzyme 57 selective phosphodiesterase 57 Cariprazine 57 Drug Candidate 57 Budesonide foam crofelemer 57 SIMCOR 57 THOSE CONTAINED IN 57 alkylating agent 57 OR OTHER EXPECTATIONS IMPLIED 57 TRISENOX ® 57 OMNARIS Nasal Spray 57 Camptosar ® 57 peptibody 57 TRANSDUR ® 57 Sudhir Agrawal D.Phil 57 DexaSite 57 generation antisense inhibitor 57 PENTASA 57 Locteron ® 57 beta 1a 57 ADP receptor antagonist 57 reflect Medicago 57 INVESTORS ARE CAUTIONED AGAINST 57 SAR# [004] 57 incyclinide 57 relapsed refractory multiple myeloma 57 candidate deforolimus 57 certain protein tyrosine 57 MAXY alpha 57 Cephalon Oncology 57 Rigel R# 57 Inc. NASDAQ ZLCS 57 GALNS 57 Romidepsin 57 prostate cancer antigen prostatic 57 concerning Xanthus 57 MGd 57 corticosteroid dexamethasone 57 Familial Adenomatous Polyposis FAP 57 TKM ApoB 57 pegylated liposomal doxorubicin 57 deforolimus 57 Thiovir 57 TYGACIL 57 SAFE HARBOUR 57 lead Aganocide compound 57 Phase 2b Trial 57 oral deforolimus 57 ENMD # 57 ThermoDox ® clinical 57 Phase IIb trials 57 etanercept Enbrel 57 ZADAXIN ® 57 CCR5 mAb 57 technology visit http:/www.genmab.com 57 Isis Alnylam 57 RANK Ligand inhibitor 57 PSN# [002] 57 bone marrow reticulin deposition 57 nilotinib Tasigna ® 57 TNF Tumor Necrosis Factor 57 OR INFORMATION 57 ® lenalidomide 57 evaluating picoplatin 57 diabetic neuropathic pain 57 subsidiaries visit http:/www.apricusbio.com 57 HCV protease inhibitor 57 programs visit http:/www.bionovo.com 57 Pruvel 57 Copegus ribavirin 57 interferon alfa 57 LAF# 57 Phase 2a Trial 57 INVESTORS SHOULD NOT 57 GVAX ® 57 novel emulsion formulation 57 Zemiva TM Trofex TM 57 Tasimelteon 57 plus prednisone prednisolone 57 HuCAL PLATINUM ® CysDisplay 57 anti CTLA 57 Pivotal Phase III 57 Presents Positive 57 dipeptidyl peptidase 4 57 relapsed acute myelogenous 57 TRX1 57 polyneuropathy HIV DSP 57 involve risksand uncertainties 57 Genz # 57 INGN 57 mGluR2 positive 57 VQD 57 baminercept 57 AVONEX ® 57 RhuDex ® 56 RELIANCE UPON ANY FORWARD 56 palonosetron hydrochloride Injection Dacogen 56 WHY ACTUAL RESULTS COULD 56 dasatinib Sprycel 56 torsemide ER 56 Pegasys peginterferon alfa 2a 56 PXD# 56 Varespladib 56 ranolazine extended release 56 myelofibrosis polycythemia vera 56 modified glutathione analog 56 Actimmune ® 56 TURNING INSIGHTS INTO HOPE 56 2 inhibitor CYT# 56 vesicular monoamine transporter 56 Fibrillex TM 56 Sapacitabine 56 Luteinizing Hormone Releasing Hormone 56 Receives Milestone Payment 56 ATPace TM 56 CAUTIONARY NOTE REGARDING FORWARD 56 lumiliximab 56 retaspimycin hydrochloride 56 Initiates Phase III 56 plus prednisone 56 migraine headaches neuropathic pain 56 Agria beliefs 56 Amigal TM 56 Aloxi injection 56 sodium thiosulfate STS 56 imatinib Gleevec ® 56 Oral NKTR 56 READERS SHOULD NOT 56 pharmacokinetic interactions 56 Initiate Phase 56 includes investigational compounds 56 products visit www.sucampo.com 56 specific lectin receptors 56 visilizumab 56 treatment naïve genotype 56 MSCRAMM ® 56 TechFaith beliefs 56 oral candidiasis 56 PLAN OR EXPECT 56 Azedra ™ 56 Looking Statements -Dunshaughlin Co Meath 56 ACCORDINGLY READERS SHOULD NOT 56 targeted radiotherapeutic 56 please visit www.middlebrookpharma.com 56 CoTherix logo 56 D aspartate NMDA receptor 56 EDEMA3 56 Vidaza ® 56 HGS ETR1 mapatumumab 56 investigational immunotherapy 56 GW# [003] 56 PI3K/Akt pathway inhibitor 56 meaningof 56 currentexpectations 56 rilonacept Injection 56 CIMZIA ™ 56 erlotinib Tarceva ® 56 gemcitabine Gemzar 56 celgosivir 56 BY THESE FORWARD 56 myeloproliferative diseases 56 Phase IIb Clinical Trial 56 Romiplostim 56 Receives Orphan Drug Designation 56 'S FUTURE PLANS 56 PRTX 56 gastrointestinal disorders ATI 56 anthracycline taxane 56 Janus kinase 56 telomerase therapeutic 56 Aflibercept 56 aripiprazole Abilify 56 Spiegelmer ® 56 Cyclooxygenase Inhibiting Nitric Oxide 56 oral Hsp# inhibitor 56 biomimetics non 56 Androxal TM 56 acetonide FA 56 5 HT2A inverse 56 RTP #i 56 pradefovir 56 JZP 56 Onalta ™ 56 TLR7 agonist 56 TO AVOID PREGNANCY WHILE 56 telaprevir VX 56 Octreolin 56 orally bioavailable 56 JAK2 Inhibitor 56 SinuNase TM 56 Vitrasert R 56 SHOULD BE READ 56 Azedra TM 56 Phase IIb Trial 56 BCG refractory carcinoma 56 Rexahn actual 56 events thrombocytopenia neutropenia 56 cisplatin gemcitabine 56 Erdene contained herein 56 Sangamo BioSciences Announces 56 pegylated interferons 56 visit http:/www.oncolyticsbiotech.com 56 Viprinex TM 56 Receives Orphan Drug 56 evaluating intravenous picoplatin 56 albiglutide 56 systemic RNAi therapeutic 56 ATTRIBUTING UNDUE CERTAINTY OR 56 PREZISTA r arm 56 Factor Receptor 56 PROVISIONS OF THE PRIVATE 56 PC DAC Exendin 56 MNTX 56 Trofex TM 56 R# #mg BID 56 CTA# Injection 56 TO IDENTIFY SUCH FORWARD 56 CIMZIA TM 56 carcinoma mCRC 56 please visit www.dyax.com 56 Long acting beta2 56 prostones 56 Somatuline R Depot 56 serious systemic Staphylococcal 56 ruxolitinib 56 small molecule thrombopoietin 56 platform HDL Mimetic 56 Curis collaborator Genentech 56 Lupus Nephritis 56 HuLuc# 56 androgen receptor modulator 56 ocular formulation 56 AMETEK filings 56 pomalidomide 56 Adenoscan R 56 Firazyr 56 CANCIDAS 56 anidulafungin 56 Completes Enrollment 56 Rebif ® 56 octreotide acetate 56 HSP# inhibitor 56 CR# vcMMAE 56 advanced carcinoid 56 rheumatoid arthritis thrombocytopenia 56 luteinizing hormone releasing 56 Zavesca R 56 hypereosinophilic syndrome 56 ACTUAL RESULTS COULD DIFFER 56 DIFICID ™ 56 Serdaxin ® 56 regorafenib 56 chronic eosinophilic leukemia 56 risks anduncertainties 56 systemic Phase 1b 56 selective immunoproteasome inhibitor 56 Vaprisol 56 www.timhortons.com en 56 Trofex ™ 56 LE SN# 56 ALS #-# 56 please visit www.rexahn.com 56 NS4A 56 neratinib 56 SCHERING PLOUGH DISCLOSURE NOTICE 56 cyclophosphamide doxorubicin vincristine 56 IPL# 56 Tarceva TM 56 bepotastine besilate nasal spray 56 SARMs 56 epothilones 56 systemically administered 56 Silodosin 56 Ocrelizumab 56 PLACE UNDUE RELIANCE ON 56 CD4 monoclonal antibody 56 TLR9 agonists 56 Panzem 56 brivaracetam 55 oral proteasome inhibitor 55 coenzyme Q# analog 55 CAUTIONARY STATEMENT UNDER 55 THR beta agonist 55 MGCD# [001] 55 standard chemotherapy regimen 55 Amrubicin 55 mGluR4 mGluR2 mGluR5 55 oxcarbazepine 55 FBPase 55 dexamethasone Decadron 55 ELACYT 55 EDEMA3 trial 55 reflect Ronn Motor 55 Ridaforolimus 55 pediatric Crohn disease 55 forward lookingstatements 55 triciribine phosphate monohydrate 55 Lenocta TM 55 oral hypoglycemic agent 55 clinical trials Archexin 55 Taxotere chemotherapy 55 Legislation Reform Act 55 oral dihydropyrimidine dehydrogenase DPD 55 Inhalation Solution 55 iniparib BSI 55 Antitumor Activity 55 class mGluR5 inhibitor 55 iobenguane 55 motexafin gadolinium Injection 55 Poly ICLC 55 Elotuzumab 55 PRADAXA 55 talactoferrin 55 INKP 55 Triapine R 55 looking statementsâ € 55 infliximab monotherapy 55 5 HT6 55 anticancer compound 55 Brentuximab Vedotin SGN 55 Xyfid TM 55 HCV replicon 55 Cautionary Statements Certain 55 Inc. Nasdaq IMGN 55 antiangiogenesis therapies 55 oral salmon calcitonin 55 OSI Geospatial Inc 55 ISTODAX 55 Darinaparsin Zinapar TM 55 CONTAINS FORWARD LOOKING STATEMENTS 55 Phase Ib study 55 Aurexis 55 Seliciclib 55 otelixizumab 55 please visit http:/www.vandapharma.com 55 GSK# [002] 55 humanized monoclonal 55 Frova ® 55 azilsartan medoxomil 55 Vidaza azacitidine 55 rash pruritus nausea 55 SUVN 55 squalamine 55 trastuzumab DM1 55 IN SUCH FORWARD 55 peripheral sensory neuropathy 55 WILL PROVE TO BE 55 www.immunogen.com 55 Indibulin Zybulin TM 55 Navelbine ® 55 GenVec cautions 55 Plicera 55 www.palatin.com 55 Delta opioid receptor 55 Epratuzumab 55 metastatic castration resistant 55 Interferon alpha 55 opioid induced bowel dysfunction 55 PORxin TM platforms 55 PLAYLOGIC assumes 55 Vitaxin 55 Allovectin 7 R 55 Trastuzumab DM1 55 SAFE HARBOR Certain 55 oral Azacitidine 55 CINTREDEKIN BESUDOTOX 55 historicalfacts 55 Velcade bortezomib 55 huN# DM1 55 clinical trials dacetuzumab SGN 55 Eltrombopag 55 demonstrated antitumor activity 55 M# rationally 55 phase IIb III 55 Testosterone MDTS R 55 generation URAT1 inhibitor 55 Initiates Clinical 55 Ecallantide 55 Intravenous CP 55 Phase 1b clinical trials 55 HZT 55 TOCOSOL Camptothecin 55 investigational hepatitis C 55 Phase 1b trial 55 low dose cytarabine 55 Behcet uveitis 55 registrational trial 55 6R BH4 55 Darinaparsin 55 theseforward looking 55 Cetrorelix 55 Tiuxetan 55 AEZS 55 HCV RNA polymerase 55 THALOMID 55 TPI ASM8 55 visit www.novabaypharma.com 55 superpotent ingredients Saben 55 Azacitidine 55 HyQ 55 topical antifungal product 55 5 fluorouracil leucovorin 55 selective androgen receptor modulator 55 suchstatements 55 DNA methyltransferase inhibitors 55 ACTUAL RESULTS MIGHT DIFFER 55 alfa 2a 55 HoFH 55 systemic immunosuppressive drugs 55 mitoxantrone plus 55 systemic anaplastic large 55 sorafenib Nexavar 55 evaluating pirfenidone 55 novel DACH platinum 55 include ClindaReach TM 55 Commence Phase 55 SENOMYX ANNOUNCES 55 Icatibant 55 taxane resistant 55 midstage clinical 55 Cutaneous T 55 pharmacologically active isomer 55 PPAR gamma agonists 55 Phase IIa trial 55 RAPTIVA 55 Mipomersen 55 Vandetanib 55 Epothilones 55 Announces Poster Presentations 55 HGS# 55 Phase III Pivotal 55 Statements Certain 55 reversible inhibitor 55 RapMAT ® 55 omega interferon 55 ATL/TV# 55 cutaneous T 55 Cancidas 55 sarcoma melanoma 55 familial amyloidotic polyneuropathy FAP 55 essential thrombocythemia ET 55 company website www.novavax.com 55 PEGylated interferon beta 1a 55 REMINYL ® 55 aplindore 55 selective A2A adenosine receptor 55 RELIANCE ON FORWARD LOOKING 55 cobiprostone 55 Pradefovir 55 whose tumors overexpress 55 adipiplon 55 Fc fusion protein 55 ELND# AZD 55 Asentar 55 Tofacitinib 55 ALN TTR 55 Phase 2a Clinical Trial 55 Clinical Trial Results 55 Hsp# inhibitor 55 gemcitabine cisplatin 55 #mg dose [002] 55 MEK inhibitors 55 metastatic hormone refractory 55 bosutinib 55 valopicitabine 55 Micromet proprietary BiTE 55 HCV SPRINT 55 Kosan dependence 55 SECTION #A OF 55 mGluR5 negative 55 small molecule defensin 55 Pruvel TM 55 N acetylgalactosamine 6 55 OvaRex ® MAb 55 Vernakalant 55 nausea arthralgia insomnia 55 preclinical pharmacokinetic 55 www.utekcorp.com 55 involverisks 55 RezularTM 55 novel antimitotic agent 55 Telintra 55 treatment naive genotype 55 â € œwill â 55 ALN TTR# 55 Syncria R 55 Traficet EN 55 Novel Oral 55 highly selective inhibitor 55 RGB # 55 cell lymphoma CTCL 55 candidate CRLX# 55 relapsed leukemia 55 apoptosis inducer 55 proteasome inhibitor 55 initiate Phase 1b 55 LNP formulations 55 antisense inhibitors 55 AFFECT MICROSEMI 'S 55 taxane chemotherapy administered 55 AQ4N 55 Irinotecan 55 candidate MyVax 55 ARCALYST ® rilonacept 55 refractory CLL 55 Granted Orphan Drug 55 signal detection CTSD 55 non porcine pancreatic 55 STATEMENTS AND 55 cytarabine daunorubicin 55 PEG irinotecan 55 candidate bevirimat PA 55 TORISEL 55 MT# MEDI 55 CLX Investments 55 MEK inhibitor 55 glucagon receptor 54 Recombinant Human 54 OmniComm intends 54 Albuferon TM 54 THEY IDENTIFY FORWARD LOOKING 54 reflecting Achillion 54 maximally tolerated dose 54 AirIQ perception 54 EOquin TM phase 54 oral antidiabetic 54 alpha folate receptor 54 Regulus Alnylam 54 AKT inhibitor 54 TOCOSOL Paclitaxel 54 reflect HRTE 54 OR ACHIEVEMENTS IMPLIED 54 TLK# 54 Dosa suffers 54 defensin mimetic antibiotic 54 Statements Statements 54 Azactam 54 Campath alemtuzumab 54 ALGRX 54 oral diclofenac 54 Severe hypersensitivity reactions 54 cyclophosphamide methotrexate 54 calcineurin inhibitors 54 DESCRIBED IN THE 54 IMA# 54 JAK Inhibitor 54 Fludara ® 54 DCCR 54 trastuzumab emtansine T DM1 54 Iluvien ® 54 KRYSTEXXA TM pegloticase 54 apricitabine ATC 54 BIM #A# 54 generation purine nucleoside 54 BCR ABL inhibitors 54 Dual Opioid 54 substantially excreted 54 idraparinux 54 IAP inhibitor 54 Hsp# Inhibitor 54 sargramostim 54 mg BID dose 54 A3 adenosine receptor 54 Viramidine 54 JAK2 inhibitor 54 EndoTAG TM 54 imatinib mesylate 54 Levetiracetam 54 Granulocyte Colony Stimulating Factor 54 intravenous acetaminophen 54 XmAb# 54 Diabetic Macular Edema 54 CINOD 54 aplastic anemia AA 54 Belinostat 54 peginterferon alfa 54 compound ISA# 54 Diamyd ® 54 thymalfasin 54 including eniluracil ADH 54 UNCERTAINTY OF FUTURE FINANCIAL 54 sitaxsentan 54 Saxagliptin 54 Phase #/#a trial 54 docetaxel Taxotere 54 small molecule tyrosine 54 tubulin inhibitor 54 SAFE HARBOR PROVISIONS OF 54 HQK 54 DermaVir Patch 54 humanized anti 54 CholeraGarde R Peru 54 HDAC Inhibitor 54 Annamycin 54 GENR 54 TÎ ² 4 54 Multiple Ascending Dose 54 BZL# 54 please visit www.advaxis.com 54 Forward lookingstatements 54 delivers fluocinolone acetonide FA 54 vildagliptin 54 successfully commercialize Iluvien 54 please visit http:/www.osip.com 54 midstage trials 54 NO ASSURANCES THAT 54 GVAX R 54 KRN# 54 salmeterol fluticasone 54 selective inverse agonist 54 recurrent metastatic ovarian cancer 54 Aurora kinase inhibitor 54 HISTORICAL ARE FORWARD LOOKING 54 Cerezyme Fabrazyme Myozyme Aldurazyme 54 BENICAR HCT 54 AS ESTIMATE ANTICIPATE BELIEVE 54 relapsed MM 54 INCB# [003] 54 TREANDA 54 Leukine ® 54 visit www.genmab.com 54 lintuzumab 54 delivery polymer matrix 54 Chemed communications 54 Hsp# inhibitors 54 hormone agonist 54 NKTR 54 reflect SpatiaLight 54 Phase #b/#a clinical 54 orally inhaled migraine 54 psoriasis rheumatoid arthritis 54 IMMU 54 Daclizumab 54 PROSTVAC VF 54 pharmacogenomic translational research 54 oral isoform selective HDAC 54 CUDC 54 MERLIN TIMI 54 cyclophilin inhibitor 54 sJIA 54 Troxatyl 54 MAXY VII